case_images: PMC5574471_01
case_images: Bilateral diffuse miliary nodular infiltrates with mediastinal and bilateral hilar adenopathy.
case_images: 10.1177_1179547617724776-fig1.jpg
case_images: PMC5574471_01_10.1177_1179547617724776-fig1.jpg
case_images: fig1-1179547617724776
case_images: Computed tomography of the chest, abdomen, and pelvis revealed miliary pulmonary pattern, patchy nodular infiltrates, and mediastinal lymphadenopathy with peritoneal and omental involvement (Figure 1).
case_images: Flow cytometric gating strategy for detection of percentage of activated T cells (CD3+CD4+ and CD3+CD8+) co-expressing CD25+CD134+ markers. (A) Viable lymphocyte gate using side and forward scatter, (B) gate on CD3+/CD4+, (C) CD3+CD4+/CD25+CD134+ co-expression after 48 hours incubation with an unstimulated sample, PPD, and ESAT-6/CFP-10 peptides mix (RD1 peptide antigen), (D) gate on CD3+/CD8+, (E) CD3+CD8+/CD25+CD134+ co-expression after 48 hours incubation with an unstimulated sample, PPD, and RD1 peptide antigen. Percentages (boxes) indicate the calculated distribution of CD25+CD134+ among CD3+CD4+ and CD3+CD8+ T cells after the subtraction of background (nil). FCS-A indicates forward scatter; PPD, purified protein derivatives; RD1, region of difference 1; SSC-A, side scatter.
case_images: 10.1177_1179547617724776-fig2.jpg
case_images: PMC5574471_01_10.1177_1179547617724776-fig2.jpg
case_images: fig2-1179547617724776
case_images: CD25+CD134+ co-expression was detected on 0.34% and 0.84% of RD1 peptide and PPD-stimulated CD3+CD4+ T cells, respectively (Figure 2).